Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.58 | N/A | +1.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.58 | N/A | +1.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains cautiously optimistic about the company's future. They emphasized the potential of new products to drive revenue.
Management expressed confidence in the company's ongoing product pipeline.
They highlighted the importance of upcoming drug launches for future growth.
Eli Lilly's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the lack of revenue data and guidance leaves some uncertainty about future performance. The stock reaction is currently not available, which may reflect investor caution amid the mixed information.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO BILBAO VIZCAYA ADR
Apr 29, 2024